Has Meredith McKean, MD received payments from drug or device companies?

Yes. Drug and device makers reported $118,348 in general payments to Meredith McKean, MD across 389 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Meredith McKean, MD did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Meredith McKean, MD come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Meredith McKean, MD

Hematology & Oncology · Nashville, TNNPI 1437425659

Payments from drug & device makers

What this record shows

This record is dominated by consulting fees: $78,831 of the $118,348 with a category attached, or 66.6%. 60 manufacturers reported payments, led by Regeneron at 34.2% of the total. 2025 is the largest year on record at $43,252, 4.1 times the $10,552 reported in 2019.

$118,348in general payments, 2019–2025

Across 389 payments — averaging $304.24 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

Regeneron$40K
Merck$26K
Regeneron Healthcare Solutions, Inc.$13K
F. Hoffmann-la Roche AG$11K
E.r. Squibb & Sons, L.L.C.$7K
Array Biopharma Inc$5K
plus $17K from 54 others

$15,939,041in research payments, 2019–2025

Across 3,399 payments — averaging $4689.33 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

Pfizer$2.3M
Merck$2.1M
Regeneron$1.9M
Sanofi US Services Inc.$1.3M
Daiichi Sankyo Inc.$1.2M
Seagen Inc.$927K
plus $6.3M from 26 others

What the payments were for

Consulting fees$78,83167%
Speaking & faculty fees$5,0354%
Travel & lodging$24,64921%
Food & beverage$9,8348%

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
Regeneron	47	$40,498
Merck	48	$25,561
Regeneron Healthcare Solutions, Inc.	52	$12,785
F. Hoffmann-la Roche AG	5	$10,808
E.r. Squibb & Sons, L.L.C.	20	$6,837
Array Biopharma Inc	11	$4,551
Daiichi Sankyo Inc.	14	$4,441
Pfizer	10	$3,126
Astellas Pharma Global Development	1	$2,180
Eisai Inc.	7	$1,914
Immunocore Limited	8	$649
Novartis	23	$583
Genentech, Inc.	3	$548
Modernatx, Inc.	2	$456
AstraZeneca(2 entities)	18	$404
Delcath Systems	2	$272
Genentech USA, Inc.	6	$191
Amgen	5	$185
Gilead	7	$143
Iovance Biotherapeutics, Inc.	3	$128
EMD Serono, Inc.	3	$125
Springworks Therapeutics, Inc.	5	$114
Lilly USA, LLC	5	$96
Johnson & Johnson	5	$96
Bayer	5	$87
Servier Pharmaceuticals LLC	4	$87
Stemline Therapeutics Inc.	4	$86
Seagen Inc.	4	$86
Sanofi	2	$73
Jazz Pharmaceuticals Inc.	3	$69
Beone Medicines USA, Inc.	3	$64
Pharmacyclics LLC, An Abbvie Company	3	$61
Taiho Oncology, Inc.	3	$56
Incyte Corporation	2	$51
Tersera Therapeutics LLC	3	$51
Astellas Pharma US Inc	2	$50
Caris MPI, Inc.	3	$47
Tempus AI, Inc	2	$47
Beigene USA, Inc.	2	$47
Avyxa Pharma, LLC	2	$46
GSK	2	$44
AVEO Pharmaceuticals, Inc.	1	$44
Bristol Myers Squibb	2	$43
Exelixis Inc.	2	$42
Mirati Therapeutics, Inc.	2	$39
Rigel Pharmaceuticals, Inc.	2	$37
Sun Pharmaceutical Industries Inc.	2	$36
CTI Biopharma Corp.	2	$36
Blueprint Medicines Corporation	1	$32
G1 Therapeutics, Inc.	1	$24
Clovis Oncology, Inc.	1	$23
Deciphera Pharmaceuticals Inc.	1	$22
Genmab U.S., Inc.	1	$21
Verity Pharmaceuticals Inc.	1	$21
Ipsen Biopharmaceuticals, Inc	1	$21
Invivyd Inc	1	$20
Celltrion USA Inc.	1	$20
Agios Pharmaceuticals, Inc.	1	$19
Pharmaessentia USA Corporation	1	$19
Accord Healthcare, Inc.	1	$19

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

LIBTAYO$35,689
BRAFTOVI$6,570
PADCEV$2,180
LENVIMA$1,785
KEYTRUDA$1,531
INLYTA$625
Non-Covered Product$548
KIMMTRAK$369
Hepzato Kit$272
OPDIVO$227
LORBRENA$150
Nplate$123
Erivedge$104

How this compares

$118,348 in reported general payments places this provider in the 85th percentile of 251 hematology & oncology providers in Tennessee.

See all hematology & oncology providers in Tennessee →

Medicare billing

Part B allowed, 2024

$1,695,126

Medicare patients

301

Services billed

43,930

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

Drug	Claims	Cost to plans & patients
Dexamethasone	15	$352
Prochlorperazine Maleate	15	$315
Oxycodone Hcl	12	$279
Prednisone	18	$65

Paid to pharmacies, not to this prescriber.

Other hematology & oncology in Nashville

Jonathan AbbasNashville$1.3M
Alan TanNashville$1.1M
Kent ShihNashville$900K
Brian RiniNashville$601K
Wade IamsNashville$601K
Krish PatelNashville$531K
Sandeep RajanNashville$465K
Todd BauerNashville$357K
Muhamed BaljevicNashville$313K
Olalekan OluwoleNashville$311K

See the full list for Tennessee →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →